ReviewExperimental and therapeutic medicine2024
Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).
Review in Experimental and therapeutic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Bridging FDA Adverse Event Reporting System (FAERS) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients.Thoracic cancer · 2026Article
- [Immune checkpoint inhibitor-related pneumonitis : Differential diagnosis strategies].Radiologie (Heidelberg, Germany) · 2026Review
- Machine learning for identifying risk factors of nosocomial infection in cancer patients with immune checkpoint inhibitor-related pneumonia.BMC infectious diseases · 2026Article
- Determinants of severity in immune checkpoint inhibitor-related pneumonitis: clinical, radiologic, and laboratory insights from real-life clinical data.BMC cancer · 2026Article
- Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature.Journal of clinical medicine · 2026Review
- Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.Probiotics and antimicrobial proteins · 2026Review
- Metagenomic next-generation sequencing for diagnosis of immune checkpoint inhibitor-associated pneumonitis: a retrospective comparative clinical performance study.Frontiers in cellular and infection microbiology · 2026Article
- [Risk Factors, Molecular Mechanisms, and Multimodal Early Warning Strategies for Immune Checkpoint Inhibitor-associated Pneumonitis in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report.Immunotherapy · 2025Article
- The modified Glasgow prognostic score serves as a robust predictor of unplanned readmission and 1-year mortality in lung cancer patients receiving immune checkpoint inhibitors.Frontiers in oncology · 2025Article
- Immune Checkpoint Inhibitors and Interstitial Lung Disease: A Comprehensive Review of Pathogenesis, Diagnosis, and Management.Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer treatment by enhancing the immune response against tumor cells. However, their influence on immune pathways can lead to immune-related adverse events such as pneumonitis, necessitating rapid diagnosis and management to prevent severe complications. These adverse events arise from the activation of the immune system by immunotherapeutic drugs, leading to immune-mediated inflammation and tissue damage in various organs and tissues throughout the body. The present review article discusses the pathophysiology, clinical presentation, diagnostic modalities and management strategies for ICI-related pneumonitis, emphasizing early recognition and tailored interventions. Future research endeavors should focus on elucidating the underlying mechanisms of pneumonitis and identifying predictive biomarkers to guide personalized treatment strategies in this evolving field of oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.